Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Nvidia slump drags Wall Street and NZ sharemarket lower
Markets Market Close

Nvidia slump drags Wall Street and NZ sharemarket lower

The S&P/NZX 50 Index closed 20 points or 0.15% down at 13,419.40.

Jamie Gray 21 Nov 2025
RBNZ reopens Wellington office after asbestos mayhem
Finance

RBNZ reopens Wellington office after asbestos mayhem

Bank tight-lipped on how many staff are home-working as asbestos-hit office reopens. 

Andy Macdonald 21 Nov 2025
Oceania Healthcare extends dividend freeze
Markets

Oceania Healthcare extends dividend freeze

The retirement village operator hasn't paid a dividend since June 2023.

John Anthony 21 Nov 2025